Q-omics provides the consensus-scored POM121L8P profile across patient tissues and cancer cell-line models. POM121L8P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, POM121L8P is differentially expressed in 2, with the highest sampling consensus in ESCA. Additionally, POM121L8P RNA expression shows 6,024 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, ESCA, and STAD as cancer lineages where POM121L8P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POM121L8P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POM121L8P survival associations across molecular data types. POM121L8P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POM121L8P RNA expression–survival associations across cancer types. High POM121L8P expression shows unfavorable associations in UCS, CHOL, KICH, BRCA, STAD and GBM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for POM121L8P RNA expression.
This table summarizes POM121L8P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for POM121L8P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POM121L8P shows higher tumor expression in ESCA and KIRC. The ESCA box plot shows higher POM121L8P RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p = .012).
This table shows molecular features associated with POM121L8P in patient tissues and cancer cell lines. In patient samples, POM121L8P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
